1256387-73-1

Basic information

• Product Name: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-
• Synonyms: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-;(1R,3S,4S)-tert-butyl 3-((2-amino-4-bromophenyl)carbamoyl)-2-azabicyclo[2.2.1]heptane-2-carboxylate
• CAS NO: 1256387-73-1
• Molecular Formula: C₁₈H₂₄BrN₃O₃
• Molecular Weight: 410.30546
• Mol File: 1256387-73-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-(1256387-73-1)
• EPA Substance Registry System: 2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-(1256387-73-1)

Safety Data

• Hazardous Substances Data: 1256387-73-1(Hazardous Substances Data)

Usage

General Description

The chemical "2-Azabicyclo[2.2.1]heptane-2-carboxylic acid, 3-[[(2-aMino-4-broMophenyl)aMino]carbonyl]-, 1,1-diMethylethyl ester, (1R,3S,4S)-" is a compound with a molecular formula C20H27N3O3Br. It is a derivative of 2-azabicyclo[2.2.1]heptane-2-carboxylic acid, and its IUPAC name is (1R,3S,4S)-3-[(2-amino-4-bromophenyl)amino]carbonyl]-1,1-dimethylethyl ester. It is a chiral compound, meaning it has a non-superimposable mirror image, and is commonly used in the synthesis of pharmaceuticals and other organic compounds. This chemical can be used as a building block in the development of pharmaceutical drugs, and its properties and potential applications make it of interest in the field of medicinal chemistry and drug development.

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 134795-25-8 (1R,3S,4S)-2-aza-bicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 
• 1181573-36-3 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-2,3-dicarboxylic acid 2-tert-butyl ester 3-methyl ester 
• 220093-41-4 (1R,3S,4S)-2-azabicyclo[2.2.1]heptane-3-carboxylic acid methyl ester 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Downstream Products

• 1256393-27-7 3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester 
• 1256387-87-7 (1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-74-2 (1R,3S,4S)-3-(6-bromo-1H-benzimidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid 1,1-dimethylethyl ester 
• 1256387-76-4 (1R,3S,4S)-tert-butyl 3-(6-(4'-(2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-1Himidazol-5-yl)biphenyl-4-yl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-75-3 (1R,3S,4S)-tert-butyl 3-(6-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazol-2-yl)-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1256387-78-6 methyl (S)-1-((S)-2-(5-(4'-(2-((1R,3S,4S)-2-((S)-2-(acetoxyamino)-3-methylbutanoyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)biphenyl-4-yl)-1Himidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
• 1273592-22-5 C₃₈H₄₄N₆O₄ 

Relevant articles and documents

Hepatitis C virus inhibitor, medical composition and application thereof

The invention provides a hepatitis C virus inhibitor, a medical composition and application thereof. The hepatitis C virus inhibitor is a compound as shown in a formula (I), or salt, hydrate or a solvent compound accepted in crystal forms and pharmacy. The compound disclosed by the invention has better hepatitis C viral protein NS5A restraining activity, has better pharmacodynamics/pharmacokinetics properties, is good in applicability and high in safety, can be used for preparing medicines for treating hepatitis C virus infection, and has favorable market development prospects.

Preparation method of ledipasvir key intermediate

The invention relates to a preparation method of a ledipasvir key intermediate, and concretely relates to a preparation method of t-butyl (1R,3S,4S)-3-(5-halo-1H-benzimidazolyl-2-yl)-2-azabicyclo[2. 2. 1]heptane-carboxylate. The method has the advantages of low price and massive commercial purchasing of a raw material, and complete avoiding of generation of disubstituted impurities.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.